Understanding and Managing Metabolic and Other Medical Issues in Psychiatry
A supplement to Clinical Psychiatry News supported by an unrestricted educational grant from Pfizer. This supplement was jointly sponsored by The Elsevier Office of Continuing Medical Education (EOCME), an ACCME accredited provider, and Clinical Psychiatry News.
The articles in this supplement are based on clinical dialogues with the faculty.
To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 16.
Introduction
Faculty
Evaluating Morbidity and Mortality Risks in Psychiatric Patients
Henry A. Nasrallah, MD
Associate Dean, Professor of Psychiatry
Neurology and Neuroscience
University of Cincinnati College of Medicine
Cincinnati, Ohio Clinical Grants: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Forest Laboratories, Inc., Janssen and Pfizer; Consultant: Abbott Laboratories, AstraZeneca, Janssen and Pfizer.
The Metabolic Syndrome in Psychiatric Patients
Jonathan M. Meyer, MD
Assistant Adjunct Professor of Psychiatry
University of California, San Diego Clinical Research/Consultant: Bristol-Myers Squibb Company; Consultant: Janssen Pharmaceutica and Pfizer Inc.
Metabolic Dysregulation Associated With Antipsychotic Drug Use
John W. Newcomer, MD
Professor of Psychiatry, Psychology and Medicine
Washington University School of Medicine
St. Louis, Mo. Grant Support/Consultant: Bristol-Myers Squibb, Janssen, and Pfizer.
Target Audience
This activity has been developed for psychiatrists and other mental healthcare professionals who are involved in the diagnosis and management of patients with psychotic illnesses and other psychiatric conditions that are treated with antipsychotic medications.
Educational Needs
The so-called conventional antipsychotic agents (including chlorpromazine, haloperidol, and thioridazine) were the first effective pharmacologic treatments for patients with schizophrenia and other psychotic illnesses. Although they still are and should be on the current roster of potential choices for therapy, the conventional antipsychotic drugs are associated with a number of serious side effects with long-term use, particularly extrapyramidal side effects (EPS) and tardive dyskinesia (TD). As a class, the second-generation antipsychotic medications—also known as atypical antipsychotic drugs—have a lower risk for EPS and TD, allow new options for patients who are treatment-resistant, manage negative as well as positive symptoms of schizophrenia, and are effective in the treatment of patients with bipolar disorders. The safety concerns with the newer antipsychotics are weight gain, hyperglycemia, type 2 diabetes mellitus, and dyslipidemia. Clinicians must be updated about the most current data concerning these issues so that they can make informed choices about which agents may be most suitable for individual patients.
Learning Objectives
After reading and studying this supplement, participants should be able to discuss:
• The metabolic side effects associated with the second-generation antipsychotic drugs.
• The recommendations of experts regarding monitoring for weight gain, new-onset (type 2) diabetes, and symptoms of the metabolic syndrome in patients taking second-generation antipsychotic drugs.
• The main benefits and risks of the classes of drugs commonly referred to as the conventional and second-generation (or atypical) antipsychotic medications.
• The current and potential indications for the second-generation antipsychotic medications.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Clinical Psychiatry News. The EOCME is accredited by the ACCME to provide continuing medical education for physicians.
The EOCME designates this educational activity for a maximum of 2.0 AMA/PRA category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.
Term of Approval: September 2005–September 30, 2006.
